Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von ...
COPENHAGEN, Denmark and CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved ...
"The data presented at ISTH underscore the potential for Hemab's impact in addressing the severe unmet needs of people with bleeding disorders," said Kate Madigan, Chief Medical Officer at Hemab. "Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results